[1] Raaphorst FM. Deregulated expression of polycomb-group oncogenes in human malignant lymphomas and epithelial tumors[J]. Hum Mol Genet, 2005,14(1):R93-R100.
[2] Cao L, Bombard J, Cintron K, et al. Bmi1 as a novel target for drug discovery in cancer[J]. J Cell Biochem, 2011,112(10):2729-2741.
[3] Huber GF, Albinger-Hegyi A, Soltermann A, et al. Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma[J]. Cancer, 2011,117(20):4659-4670.
[4] Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation[J]. J Clin Invest, 2004,113(2):175-179.
[5] Cui H, Hu B, Li T, et al. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells[J]. Am J Pathol, 2007,170(4):1370-1378.
[6] Mihic-Probst D, Kuster A, Kilgus S, et al. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma[J]. Int J Cancer, 2007,121(8):1764-1770.
[7] Molofsky AV, He S, Bydon M, et al. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways[J]. Genes Dev, 2005,19(12):1432-1437.
[8] Nakauchi H, Oguro H, Negishi M, et al. Polycomb gene product Bmi-1 regulates stem cell self-renewal[J]. Ernst Schering Res Found Workshop, 2005,(54):85-100.
[9] Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells[J]. Nature, 2003,423(6937):302-305.
[10] van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene[J]. Genes Dev, 1994,8(7):757-769.
[11] Dimri GP, Martinez JL, Jacobs JJ, et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells[J]. Cancer Res, 2002,62(16):4736-4745.
[12] Hosen N, Yamane T, Muijtjens M,et al. Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation of bmi-1 expression in normal and leukemic hematopoietic cells[J]. Stem Cells, 2007,25(7):1635-1644.
[13] Gao R, Chen S, Kobayashi M, et al. Bmi1 promotes erythroid development through regulating ribosome biogenesis[J]. Stem Cells, 2015,33(3):925-938.
[14] Paranjape AN, Balaji SA, Mandal T,et al. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog[J]. BMC Cancer, 2014,14:785.
[15] Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53[J]. Cell, 1998,92(6):713-723.
[16] Weber JD, Taylor LJ, Roussel MF, et al. Nucleolar Arf sequesters Mdm2 and activates p53[J]. Nat Cell Biol, 1999,1(1):20-26.
[17] Chen Y, Li L, Ni W, et al. Bmi1 regulates auditory hair cell survival by maintaining redox balance[J]. Cell Death Dis, 2015, 6:e1605.
[18] Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment[J]. J Clin Invest, 2011,121(10):3804-3809.
[19] Dudley AC, Khan ZA, Shih SC, et al. Calcification of multipotent prostate tumor endothelium[J]. Cancer Cell, 2008,14(3):201-211.
[20] Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors[J]. Cancer Res, 2008,68(11):4311-4320.
[21] Song LB, Zeng MS, Liao WT, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells[J]. Cancer Res, 2006,66(12):6225-6232.
[22] Song LB, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells[J]. J Clin Invest, 2009,119(12):3626-3636.
[23] Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment[J]. Pro Na Acad Sci U S A, 2009,106(38):16281-16286.
[24] Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells[J]. Int J Biol Sci, 2011,7(5):517-535.
[25] Wiederschain D, Chen L, Johnson B, et al. Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis[J]. Mol Cell Biol, 2007,27(13):4968-4979.
[26] Abdouh M, Facchino S, Chatoo W, et al. BMI1 sustains human glioblastoma multiforme stem cell renewal[J]. J Neurosci, 2009,29(28):8884-8896.
[27] Yang MH, Hsu DS, Wang HW, et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition[J]. Nat Cell Biol, 2010,12(10):982-992.
[28] Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease[J]. Cell, 2009,139(5):871-890.
[29] Raimondi C, Gianni W, Cortesi E, et al. Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease[J]. Curr Cancer Drug Targets, 2010,10(5):496-508.
[30] Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs[J]. Nat Cell Biol, 2009,11(12):1487-1495.
[31] Kim JH, Yoon SY, Kim CN, et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins[J]. Cancer Lett, 2004,203(2):217-224.
[32] Leung C, Lingbeek M, Shakhova O, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas[J]. Nature, 2004,428(6980):337-341.
[33] Chen H, Zhou L, Wan G, et al. BMI1 promotes the progression of laryngeal squamous cell carcinoma[J]. Oral Oncology, 2011,47(6):472-481.
[34] Kim JH, Yoon SY, Jeong SH, et al. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer[J]. Breast, 2004,13(5):383-388.
[35] Lukacs RU, Memarzadeh S, Wu H, et al. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation[J]. Cell Stem Cell, 2010,7(6):682-693.
[36] Li DW, Tang HM, Fan JW, et al. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer[J]. J Cancer Res Clin Oncol, 2010,136(7):997-1006.
[37] Liu JH, Song LB, Zhang X, et al. Bmi-1 expression predicts prognosis for patients with gastric carcinoma[J]. J Surg Oncol , 2008,97(3):267-272.
[38] Zhang XW, Sheng YP, Li Q, et al. BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer[J]. Mol Cancer, 2010,9:40.
[39] Zhang L, Sullivan P, Suyama J, et al. Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer[J]. Mol Cancer Res, 2010,8(2):278-290.
[40] Guo BH, Feng Y, Zhang R, et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer[J]. Mol Cancer, 2011,10(1):10.
[41] Wang E, Bhattacharyya S, Szabolcs A, et al. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer[J]. PloS One, 2011,6(3):e17918.
[42] Li J, Gong LY, Song LB, et al. Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB pathway[J]. Am J Pathol, 2010,176(2):699-709.
[43] Xu ZY, Tang JN, Xie HX, et al. 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells[J]. Int J Biol Sci, 2015,11(3):284-294.
[44] Siddique HR, Parray A, Tarapore RS, et al. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling[J]. PloS One, 2013,8(5):e60664.
[45] Liu W, Feng JQ, Shen XM, et al. Two stem cell markers, ATP-binding cassette, G2 subfamily (ABCG2) and BMI-1, predict the transformation of oral leukoplakia to cancer: a long-term follow-up study[J]. Cancer, 2012,118(6):1693-1700.
[46] Feng JQ, Xu ZY, Shi LJ, et al. Expression of cancer stem cell markers ALDH1 and Bmi1 in oral erythroplakia and the risk of oral cancer[J]. J Oral Pathol Med, 2013,42(2):148-153.
[47] Ma L, Wang H, Yao H, et al. Bmi1 expression in oral lichen planus and the risk of progression to oral squamous cell carcinoma[J]. Ann Diagn Pathol, 2013,17(4):327-330.
[48] Chou CH, Yang NK, Liu TY, et al. Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer[J]. Cancer Res, 2013,73(2):953-966.
[49] Yu CC, Lo WL, Chen YW, et al. Bmi-1 regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells[J/OL]. Stem Cells Int, 2011, 2011:609259[2015-08-30]. http://dx.doi.org/10.1155/2011/609259.
[50] Kang MK, Kim RH, Kim SJ, et al. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival[J]. Br J Cancer, 2007,96(1):126-133.
[51] Major AG, Pitty LP, Farah CS. Cancer stem cell markers in head and neck squamous cell carcinoma[J/OL]. Stem Cells Int, 2013,2013:319489[2005-08-30]. http://dx.doi.org/10.1155/2013/319489.
[52] Chen YC, Chang CJ, Hsu HS, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1[J]. Oral Oncol, 2010,46(3):158-165.
[53] Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma[J]. Proc Natl Acad Sci U S A, 2007,104(3):973-978.
[54] Zhang P, Zhang Y, Mao L, et al. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes[J]. Cancer Lett, 2009,277(2):227-234.
[55] Kurihara K, Isobe T, Yamamoto G, et al. Expression of BMI1 and ZEB1 in epithelial-mesenchymal transition of tongue squamous cell carcinoma[J]. Oncol Rep, 2015,34(2):771-778.
[56] Li Z, Wang Y, Yuan C, et al. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer[J]. Lab Invest, 2014,94(12):1431-1445. |
粤ICP备18050693号 粤公网安备 44010502002066号
本作品遵循Creative Commons Attribution 3.0 License授权许可.
